EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The renal apical sodium‐dependent bile acid transporter expression rescue attenuates renal damage in diabetic nephropathy via farnesoid X receptor activation

Youmei Li, Shuguang Pang, Honggang Guo, Shuo Yang

Nephrology · 2024-10 · 29 (10) · 627-635

DOI: 10.1111/nep.14338 ↗
AbstractBibliografische Angaben

Abstract

Abstract Aim Bile acids (BA) function as signalling molecules regulating glucose‐lipid homeostasis and energy expenditure. However, the expression of the apical sodium‐dependent bile acid transporter (ASBT) in the kidney, responsible for renal BA reabsorption, is downregulated in patients with diabetic kidney disease (DKD). Using the db/db mouse model of DKD, this study aimed to investigate the effects of rescuing ASBT expression via adeno‐associated virus‐mediated delivery of ASBT ( AAV ASBT) on kidney protection. Methods Six‐week‐old male db/db mice received an intraparenchymal injection of AAV ASBT at a dose of 1 × 10 11 viral genomes (vg)/animal and were subsequently fed a chow diet for 2 weeks. Male db/m mice served as controls. For drug treatment, daily intraperitoneal (i.p.) injections of the farnesoid X receptor (FXR) antagonist guggulsterone (GS, 10 mg/kg) were administered one day after initiating the experiment. Results AAV ASBT treatment rescued renal ASBT expression and reduced the urinary BA output in db/db mice. AAV ASBT treatment activated kidney mitochondrial biogenesis and ameliorated renal impairment associated with diabetes by activating FXR. In addition, the injection of FXR antagonist GS in DKD mice would reverse these beneficial effects by AAV ASBT treatment. Conclusion Our work indicated that restoring renal ASBT expression slowed the course of DKD via activating FXR. FXR activation stimulates mitochondrial biogenesis while reducing renal oxidative stress and lipid build up, indicating FXR activation's crucial role in preventing DKD. These findings further suggest that the maintenance of renal BA reabsorption could be a viable treatment for DKD.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →